Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
Open accessThe DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations to PKD1 or PKD2, triggering progressive cystogenesis and typically leading to end-stage renal disease in midlife. The phenotypic spectrum, however, ranges from in utero onset to adequate renal function at old age. Recent patient data suggest that the disease is dosage dependent, where incompletely penetrant alleles influence disease severity. Here, we have developed a knockin mouse model matching a likely disease variant, PKD1 p.R3277C (RC), and have proved that its functionally hypomorphic nature modifies the ADPKD phenotype. While Pkd1+/null mice are normal, Pkd1RC/null mice have rapidly progressive disease, and Pkd1RC/RC animals develop gradual cystogenesis. These models effectively mimic the pathophysiological features of in utero-onset and typical ADPKD, respectively, correlating the level of functional Pkd1 product with disease severity, highlighting the dosage dependence of cystogenesis. Additionally, molecular analyses identified p.R3277C as a temperature-sensitive folding/trafficking mutant, and length defects in collecting duct primary cilia, the organelle central to PKD pathogenesis, were clearly detected for the first time to our knowledge in PKD1. Altogether, this study highlights the role that in trans variants at the disease locus can play in phenotypic modification of dominant diseases and provides a truly orthologous PKD1 model, optimal for therapeutic testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies revealed that mutations in Prksch or Sec63 greatly reduce the expression, stability and proper trafficking of polycystin-1 (PC1), leading to cyst formation in a dose-dependent manner [426,427].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [427]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and proteomic profiling of exosomes in human urine
Pisitkun, T., Shen, R.-F., & Knepper, M. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403453101 · Cited by 2,174 · cited 2×
“21, 22).”
Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells
Nauli, S. M., Alenghat, F. J., Luo, Y., Williams, E., Vassilev, P., Li, X., Elia, A. E. H., Lu, W., Brown, E. M., Quinn, S. J., et al. (2003) · Nature Genetics · doi:10.1038/ng1076 · Cited by 2,057 · cited 2×
“However, in PKD1, the majority of studies have not detected cilia length defects, but the data are not conclusive, as these studies were largely conducted by light microscopy using cultured cells (14, 15, 80, 81).”
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationPKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406 · cited 1×
“3) and PKD2 (4q21), mutated in approximately 85% and 15% of cases, respectively (3–5).”
Hildebrandt, F., Benzing, T., & Katsanis, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010172 · Cited by 1,331
A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout Mutations
Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013 · cited 1×
“A β -lactamase expression cassette flanked with a 3 ′ Sal I site was recom-bineered into IVS30, using the DY380 E. coli strain (63).”
Yoder, B. K., Hou, X., & Guay-Woodford, L. M. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000029587.47950.25 · Cited by 935
Hughes, J., Ward, C. J., Peral, B., Aspinwall, R., Clark, K., San Millán, J. L., Gamble, V., & Harris, P. C. (1995) · Nature Genetics · doi:10.1038/ng0695-151 · Cited by 910 · cited 1×
“82, 83).”
Self-citationDise, T. E. P. K. (1994) · Cell · doi:10.1016/0092-8674(94)90137-6 · Cited by 903
Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents
Hanaoka, K., Qian, F., Boletta, A., Bhunia, A. K., Piontek, K., Tsiokas, L., Sukhatme, V. P., Guggino, W. B., & Germino, G. G. (2000) · Nature · doi:10.1038/35050128 · Cited by 818 · cited 1×
“One possibility is that the PC complex acts as a mechanosensor, signaling via a Ca 2+ influx through PC-2, a TRP channel, after fluid flow detection by PC-1 (14, 16, 20).”
Research works printed but not linked: 1
- Dalgaard, 1957, Acta Med Scand Suppl., 328, 1
Cited by
Items 201–300 of 480
Torres, J. A., Holznecht, N. J., Asplund, D. A., Kroes, B. C., Amarlkhagva, T., Haeffner, M. M., Sharpe, E. H., Koestner, S., Strubl, S., Schimmel, M. F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110773 · Cited by 17
Up-Regulation of DNA Damage Response Signaling in Autosomal Dominant Polycystic Kidney Disease
Zhang, J. Q. J., Saravanabavan, S., Chandra, A. N., Munt, A., Wong, A. T. Y., Harris, P. C., Harris, D. C. H., McKenzie, P. R., Wang, Y., & Rangan, G. K. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.011 · Cited by 16
Self-citationPagliarini, R., & Podrini, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.740087 · Cited by 16
“The pathophysiology behind ADPKD is not completely understood, but a “threshold model” of cytogenesis is supported by previous studies (101–103).”
ResultAlzahrani, O. R., Alatwi, H. E., Alharbi, A. A., Alessa, A. H., Al‐Amer, O. M., Alanazi, A. F. R., Shams, A. M., Alomari, E., Naser, A. Y., Alzahrani, F. A., et al. (2022) · Medicina · doi:10.3390/medicina58111657 · Cited by 16
Childhood Polycystic Kidney Disease
Patil, A., Sweeney, W. E., Avner, E. D., & Pan, C. G. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch2 · Cited by 16
“Molecular pathogenesis [See chapters 7 to 16, this text] It is clear that standard Mendelian genetics are inadequate to predict the severity or the rate of progression of the renal disease nor the severity of extrarenal manifestations in childhood PKD. Complex transcriptional events are clearly major disease modifiers…”
BackgroundInfluentialPrimary cilia suppress Ripk3-mediated necroptosis
Kieckhöfer, E., Slaats, G. G. G., Ebert, L. K., Albert, M., Dafinger, C., Kashkar, H., Benzing, T. R., & Schermer, B. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01272-2 · Cited by 16
Autosomal dominant polycystic kidney disease
Ong, A. C. M., Carriazo, S. M., Mingyao, B., Torrá, R., & Pei, Y. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00046-2 · Cited by 15
Yanda, M. K., & Cebotaru, L. (2021) · The FASEB Journal · doi:10.1096/fj.202101315r · Cited by 15
Modeling Pkd1 gene-targeted strategies for correction of polycystic kidney disease
Kurbegovic, A., Pacis, R. C., & Trudel, M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.03.016 · Cited by 15
Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease
Weisser, I. D., Eckberg, K., D’Amico, S., Buttram, D. J., & Aboudehen, K. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000265 · Cited by 15
Primary cilia and actin regulatory pathways in renal ciliopathies
Kalot, R. K., Sentell, Z. T., Kitzler, T. M., & Torban, E. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1331847 · Cited by 15
“In ADPKD, it is hypothesized that a “ second-hit ” in the polycystin genes that reduces the PC function is required for cystogenesis in renal epithelial cells (127, 138, 144).”
BackgroundMutation Type and Intracranial Aneurysm Formation in Autosomal Dominant Polycystic Kidney Disease
Kataoka, H., Akagawa, H., Ushio, Y., Sato, M., Manabe, S., Makabe, S., Kawachi, K., Akihisa, T., Iwasa, N., Yoshida, R. Y., et al. (2022) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.121.000203 · Cited by 15
“Generally, cyst formation in ADPKD is considered to be caused by a loss of function in which somatic mutations (2-hit model of ADPKD) 46–48 and hypomorphic models 49,50 play crucial roles.”
Hypomorphic PKD1 Alleles Impact Disease Variability in Autosomal Dominant Polycystic Kidney Disease
Gulati, A., Dahl, N. K., Hartung, E. A., Clark, S. L., Moudgil, A., Goodwin, J. E., & Somlo, S. (2023) · Kidney360 · doi:10.34067/kid.0000000000000064 · Cited by 15
Shitamori, F., Nonogaki, A., Motegi, T., Matsumoto, Y., Sakamoto, M., Tanizawa, Y., Nakamura, Y., Yonezawa, T., Momoi, Y., & Maeda, S. (2023) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x231185393 · Cited by 15
“2 the disease occurs when the PC1 levels drop below a certain threshold and do not necessarily have to be 28 at zero [14, 17].”
BackgroundRoy, K., & Marin, E. P. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4224-6 · Cited by 15
Genetic Kidney Diseases (GKDs) Modeling Using Genome Editing Technologies
Gómez-García, F., Pulleiro, R. M., Carrera, N., Allegue, C., & García-González, M. Á. (2022) · Cells · doi:10.3390/cells11091571 · Cited by 14
Chen, Y., Chiang, H.-C., Litchfield, P., Pena, M. J., Juang, C., & Riley, D. J. (2014) · Journal of Biomedical Science · doi:10.1186/s12929-014-0063-5 · Cited by 14
Li, D., Dawson, J., & Gunton, J. E. (2024) · Nutrients · doi:10.3390/nu17010145 · Cited by 13
The role of PPARα in autosomal dominant polycystic kidney disease
Lakhia, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000615 · Cited by 14
“The Pkd1 mouse is based on a human PKD1 mutation that results in a hypomorphic PKD1 allele [22].”
BackgroundDecuypere, J.-P., Giel, D. V., Janssens, P., Dong, K., Somlo, S., Cai, Y., Mekahli, D., & Vennekens, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413511 · Cited by 13
Naranjo, J., Utiel, F. J. B., Rocha, J. L., Salgueira, M., Martín-Gómez, A., Orellana, C., Morales, A., Vallejo, F., Hidalgo, P., Rodríguez, F., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.987092 · Cited by 13
“This mutation causes an alteration in the synthesis of polycystin-1 and two proteins and an accumulation of intracellular cyclic adenosine monophosphate (cAMP) that promotes the development and growth of renal cysts (3).”
BackgroundArkhipov, S. N., Potter, D. L., Sultanova, R. F., Ilatovskaya, D. V., Harris, P. C., & Pavlov, T. S. (2023) · Physiological Reports · doi:10.14814/phy2.15652 · Cited by 13
Self-citationYuajit, C., Muanprasat, C., Homvisasevongsa, S., & Chatsudthipong, V. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.165 · Cited by 13
Wu, J., Cheng, A. S., Weimbs, T., Harris, P. C., Zhou, J. X., & Li, X. (2025) · The FASEB Journal · doi:10.1096/fj.202501605r · Cited by 14
“Pkd1 RC/RC mice is a milder hypomorphic ADPKD mouse model with Arg3277Cys (RC) mutation, carrying an arginine (R) to cystine (C) mutation as in ADPKD patients [23].”
Self-citationPerretta‐Tejedor, N., Jafree, D. J., & Long, D. A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109624 · Cited by 12
Jamadar, A., Ward, C. J., Remadevi, V., Varghese, M. M., Pabla, N., Gumz, M. L., & Rao, R. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000528 · Cited by 12
Self-citationEmerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease
Molinari, E., & Sayer, J. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1372282 · Cited by 12
The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease
Zhang, J. Q. J., Saravanabavan, S., Munt, A., Wong, A. T. Y., Harris, D. C. H., Harris, P. C., Wang, Y., & Rangan, G. K. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.6 · Cited by 12
Self-citationEdwards, M. E., Periyanan, S., Anaam, D. A., Gregory, A., & Kline, T. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.07.040 · Cited by 12
Quinomycin A reduces cyst progression in polycystic kidney disease
Radadiya, P. S., Thornton, M. M., Daniel, E. A., Idowu, J. Y., Wang, W., Magenheimer, B. S., Subramaniam, D., Tran, P. V., Calvet, J. P., Wallace, D. P., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002490r · Cited by 12
Daneshgar, N., Liang, P., Lan, R. S.-L., Horstmann, M. M., Pack, L., Bhardwaj, G., Penniman, C. M., O'Neill, B. T., & Dai, D. (2021) · Kidney International · doi:10.1016/j.kint.2021.12.006 · Cited by 12
Germline Mutations for Kidney Volume in ADPKD
Kataoka, H., Yoshida, R. Y., Iwasa, N., Sato, M., Manabe, S., Kawachi, K., Makabe, S., Akihisa, T., Ushio, Y., Teraoka, A., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.12.012 · Cited by 12
“Although the 2-hit model is an important mechanism of ADPKD, recent evidence has suggested that PKD progression or severity is influenced by the level of functional polycystins (haploinsufficiency/loss of function model).(41,42) In human genetic diseases, haploinsufficiency or loss of function is caused by the nonsens…”
BackgroundPrimary cilia and renal cysts: does length matter?
Ong, A. C. M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft354 · Cited by 12
Ta, M. H. T., Liuwantara, D., & Rangan, G. K. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0193-3 · Cited by 12
“More recently, the “gene dosage” hypothesis has proposed that a second somatic mutation is not prerequisite for cystogenesis, but rather that cystogenesis commences if the amount of functional polycystin varies outside a certain range [27, 62, 63].”
BackgroundAmbrosini, E., Montanari, F., Cristalli, C. P., Capelli, I., Scola, C. L., Pasini, A., & Graziano, C. (2023) · Genes · doi:10.3390/genes14061230 · Cited by 11
“Cellular studies have shown that this amino acid change leads to PC1 misfolding, resulting in increased ER retention and reduced surface expression [37].”
BackgroundPaces-Fessy, M. (2014) · médecine/sciences · doi:10.1051/medsci/20143011017 · Cited by 11
“Elle peut aussi varier selon le seuil de protéines fonctionnelles présentes, indiquant un effet de dosage génique [29].”
BackgroundCharacterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD
Pereira, R. C., Gitomer, B. Y., Chonchol, M., Harris, P. C., Noche, K. J., Salusky, I. B., & Albrecht, L. V. (2021) · JBMR Plus · doi:10.1002/jbm4.10464 · Cited by 11
Self-citationEckberg, K., Weisser, I. D., Buttram, D. J., Somia, N. V., Igarashi, P., & Aboudehen, K. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00016.2022 · Cited by 11
Atwood, D. J., Brown, C. N., Holditch, S. J., Pokhrel, D., Thorburn, A. M., Hopp, K., & Edelstein, C. L. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109760 · Cited by 12
Self-citationZhang, J. Q. J., Saravanabavan, S., & Rangan, G. K. (2021) · Cells · doi:10.3390/cells10030532 · Cited by 11
“The timepoints chosen for follow-up were based on disease progression described by previous studies [17,43,45,46].”
MethodHosseinpour, M., Ardalani, F., Mohseni, M., Beheshtian, M., Arzhangi, S., Ossareh, S., Najmabadi, H., Nobakht, A., Kahrizi, K., & Broumand, B. (2022) · Archives of Iranian Medicine · doi:10.34172/aim.2022.95 · Cited by 12
Wang, E., Chiou, Y., Jeng, W. Y., Lin, H.-K., Lin, H., Chin, H.-J. G., Wang, C. L., Yu, S.-S., Tsai, S.-C., Chiang, C.-Y., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.005 · Cited by 11
Zhang, J. Q. J., Saravanabavan, S., Cheng, K. M., Raghubanshi, A., Chandra, A. N., Munt, A., Rayner, B. S., Zhang, Y., Chau, K., Wong, A. T. Y., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248400 · Cited by 10
“By histology, Pkd1 mice developed focal kidney cyst formation, as expected [33], but the percentage kidney cyst area was not altered in Fig 3.”
BackgroundMethodIn vivo base editing rescues ADPKD in a humanized mouse model
Cheng, A. S., Li, L. X., Zhou, J. X., Harris, P. C., Calvet, J. P., & Li, X. (2025) · Nature Communications · doi:10.1038/s41467-025-65997-1 · Cited by 10
“Text Clarity and Grammar: The clarity of the text should be improved throughout.”
Self-citationJafree, D. J., Perera, C., Ball, M., Tolomeo, D., Pomeranz, G., Wilson, L., Davis, B. M., Mason, W. J., Funk, E. M., Kolatsi‐Joannou, M., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052024 · Cited by 10
“We therefore turned to Pkd1 RC/RC mice, a representative animal model that mimics the slow temporal progression of human ADPKD (Hopp et al., 2012; Sieben and Harris, 2023).”
InfluentialGeneration of c-Myc transgenic pigs for autosomal dominant polycystic kidney disease
Ye, J., He, J. H., Li, Q., Feng, Y., Bai, X., Chen, X., Zhao, Y., Hu, X., Yu, Z., & Li, N. (2013) · Transgenic Research · doi:10.1007/s11248-013-9707-6 · Cited by 10
“…Happe et al. 2009; Bell et al. 2011; Weimbs 2011), and the threshold effect hypothesis (hypomorphic or overexpressed alleles) (Pritchard et al. 2000; Lantinga-van Leeuwen et al. 2004; Hassane et al. 2007; Kim et al. 2008; Burtey et al. 2008; Kurbegovic et al. 2010; Harris 2010; Hopp et al. 2012).”
Prostaglandins as potential targets for the treatment of polycystic kidney disease
Aukema, H. M. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102220 · Cited by 10
Nie, X., & Arend, L. J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.97 · Cited by 10
Clinical Trials in Autosomal Dominant Polycystic Kidney Disease
Yu, A. S. L., Ters, M. E., & Winklhofer, F. T. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch6 · Cited by 10
Childhood Polycystic Kidney Disease
Sweeney, W. E., Gunay‐Aygun, M., Patil, A., & Avner, E. D. (2015) · Springer eBooks · doi:10.1007/978-3-662-43596-0_32 · Cited by 10
Activation of polycystin-1 signaling by binding of stalk-derived peptide agonists
Pawnikar, S., Magenheimer, B. S., Joshi, K., Nevarez-Munoz, E., Haldane, A., Maser, R. L., & Miao, Y. (2024) · eLife · doi:10.7554/elife.95992 · Cited by 9
“ADPKD severity is dependent on the functional level of PC1, and as such, therapies designed to increase the level of PC1 protein, and its functionality are currently being pursued ( Hopp et al., 2012 ; Cai et al., 2014 ; Hofherr et al., 2016 ; Krappitz et al., 2016 ; Lakhia et al., 2022 ).”
In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease
Ibel, A., Bhardwaj, R., Yılmaz, D. E., Kong, S., Wendlinger, S., Cordero, C., Papaioannou, D., Papazian, M., Schönauer, R. A.-R., Meng, Q., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.026 · Cited by 10
“7,8 Consequently, loss-of-function variants are associated with more severe phenotypes, whereas milder, late-onset forms of the disease are linked to hypomorphic missense mutations that partially preserve polycystin function.”
Identified eleven exon variants in PKD1 and PKD2 genes that altered RNA splicing by minigene assay
Liu, X., Shi, X., Xin, Q., Liu, Z., Pan, F., Qiao, D., Chen, M., Zhang, Y., Guo, W., Li, C., et al. (2023) · BMC Genomics · doi:10.1186/s12864-023-09444-9 · Cited by 9
“Increasing evidence suggests that PC1 and PC2 inhibit cyst formation in a dose-dependent manner, and the cystogenesis occurs when the concentration of abnormal PC1 or PC2 falls below a certain threshold [35, 36].”
BackgroundPark, E. Y. J., Kwak, M., Ha, K., & So, I. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2095-7 · Cited by 9
Hajirezaei, F., Ghaderian, S. M. H., Hasanzad, M., Nafar, M., Ghadiani, M. H., Biglari, S., Sohrabifar, N., & Jafari, H. (2020) · Reports of Biochemistry and Molecular Biology · doi:10.29252/rbmb.9.2.193 · Cited by 9
“Several indices, including the nature of the mutated gene, and patient age, gender, kidney function, and kidney volume can be used to predict disease progression (5, 6).”
BackgroundNakatani, S., Nishide, K., Okuno, S., Ishimura, E., Kabata, D., Morioka, F., Machiba, Y., Uedono, H., Tsuda, A., Shoji, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89480-1 · Cited by 9
Tan, A. Y., Blumenfeld, J. D., & Rennert, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_19 · Cited by 9
Li, X., Ran, J., Zhou, H., He, J., Qiu, Z., Wang, S., Wu, M., Zhu, S., An, Y.-P., Ma, A., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00937-z · Cited by 9
Orisio, S., Noris, M., Rigoldi, M., Bresin, E., Perico, N., Trillini, M., Donadelli, R., Perna, A., Benigni, A., & Remuzzi, G. (2023) · The Nephron journals/Nephron journals · doi:10.1159/000530657 · Cited by 9
“Functional levels of PC1 and PC2 are essential to inhibiting cystogenesis [27].”
BackgroundRoy, S. G., Li, Z., Guo, Z., Long, K. T., Rehrl, S., Tian, X., Dong, K., & Besse, W. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000164 · Cited by 9
How Does ADPKD Severity Differ Between Family Members?
Yeung, K., Fryml, E. M., & Lanktree, M. B. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.01.053 · Cited by 9
“29 It appears likely that both “ hap-loinsuf fi ciency ” and “ two hit ” models contribute to cyst formation and growth.”
Oto, Ö. A., & Edelstein, C. L. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000525944 · Cited by 9
“In the Pkd1RC/RC mouse, there is a dosage effect on the phenotype [20].”
BackgroundInfluentialRenal double negative T cells: unconventional cells in search of a function
Nemenoff, R. A., Kleczko, E. K., & Hopp, K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.107 · Cited by 8
“In the orthologous ADPKD model, Pkd1 (17,18), polycystic kidney disease severity increases with age and overall disease severity is more pronounced in the Balb/c versus C57Bl/6 strain; (B) renal frequency of DN T cells as percent of all renal αβ T cells.”
BackgroundMethodSelf-citationIdentification of ADPKD-Related Genes and Pathways in Cells Overexpressing PKD2
Zhang, Z., Dang, Y., Wang, Z., Wang, H., Pan, Y., & He, J. H. (2020) · Genes · doi:10.3390/genes11020122 · Cited by 8
“, the two-hit [7,8], third hit/renal injury [9–11], and dosage effect (reduced or increased PKD1/2 expression) [12,13], have been proposed to explain the etiology of ADPKD.”
BackgroundFunctions of the primary cilium in the kidney and its connection with renal diseases
Clearman, K. R., Haycraft, C. J., Croyle, M. J., Collawn, J. F., & Yoder, B. K. (2023) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2023.07.001 · Cited by 8
Tsilosani, A., Gao, C., Chen, E., Lightle, A. R., Shehzad, S. A., Sharma, M., Tran, P. V., Bates, C. M., Wallace, D. P., & Zhang, W. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000309 · Cited by 8
“24 The Thm1CKO is an inducible ciliary PKD model.”
Busch, T., Neubauer, B., Schmitt, L., Cascante, I., Knoblich, L., Wegehaupt, O., Schöler, F., Tholen, S., Hofherr, A., Schell, C., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401763r · Cited by 8
“13,21 The precise mechanism how the PC1-PC2 complex regulates tubular morphology is still unknown.”
Scarlat, A., Trionfini, P., Rizzo, P., Conti, S., Longaretti, L., Breno, M., Longhi, L., Xinaris, C., Remuzzi, G., Benigni, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94855-9 · Cited by 8
“In ADPKD, large and severe cysts are found predominantly in the renal CD 52–54 hinting that there may be cell-autonomous processes that drive disease progression.”
Ha, K., Loeb, G. B., Park, M., Gupta, M., Akiyama, Y., Argiris, J., Pinedo, A., Park, C. H., Brandes, N., Ritu, F., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001008 · Cited by 8
Cheng, T., Mariappan, A., Langner, E., Shim, K., Gopalakrishnan, J., & Mahjoub, M. R. (2024) · JCI Insight · doi:10.1172/jci.insight.172047 · Cited by 8
“We utilized a recently developed slow-onset ADPKD mouse model harboring a point mutation in Pkd1 (43).”
BackgroundMethodInfluentialEmerging Therapies for Childhood Polycystic Kidney Disease
Sweeney, W. E., & Avner, E. D. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00077 · Cited by 8
“These include hypomorphic or incompletely penetrant alleles (50); PKD1 or PKD2 homozygosity (47); compound heterozygosity (51); trans-heterozygosity (52); somatic and germ-line mosaicism (53); epigenetic regulators (54–57); genetic modifiers (58); co-inheritance of a PKD1 or PKD2 mutation and an additional cyst-causin…”
BackgroundNovel long-range regulatory mechanisms controlling PKD2 gene expression
Moisan, S., Levon, S., Gall, É. C.-L., Meur, Y. L., Audrézet, M., Dostie, J., & Férec, C. (2018) · BMC Genomics · doi:10.1186/s12864-018-4892-6 · Cited by 8
Zubidat, D., Hanna, C., Randhawa, A. K., Smith, B. H., Chedid, M., Kaidbay, D.-H. N., Nardelli, L., Mkhaimer, Y. G., Neal, R. M., Madsen, C. D., et al. (2023) · Bone Reports · doi:10.1016/j.bonr.2023.101655 · Cited by 8
Self-citationChildhood Polycystic Kidney Disease
Sweeney, W. E., Gunay‐Aygun, M., Patil, A., & Avner, E. D. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_32-1 · Cited by 8
Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease
Chen, C. Y., Hadla, M., Khambati, I., Kashyap, S., Westerfield, V., Fedeles, S. V., Besse, W., Hopp, K., Harris, P. C., Patel, V., et al. (2025) · Kidney360 · doi:10.34067/kid.0000001109 · Cited by 8
“19 Equally remarkable, recent studies in mouse models revealed that re-expression of Pkd1 or Pkd2 after gene inactivation not only halted progression but reversed disease: cysts regressed, tubular architecture normalized, and fi brosis and in fl ammation abated.”
Self-citationHwang, S.-H., Choi, K., Badgandi, H., White, K. A., Xun, Y., Woodward, O. M., Qian, F., & Mukhopadhyay, S. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1012008 · Cited by 7
“Loss of PC1/2 has been shown to increase cilia length in ADPKD mouse models [13,36,37] and in human patients [38].”
Yang, Y., Zhou, J., Zhang, D., Lv, J., Chen, M., Wang, C., Song, M., He, F., Song, S., & Mei, C. (2023) · Inflammation · doi:10.1007/s10753-023-01806-5 · Cited by 7
Yasinoglu, S. A., Kuipers, T. B., Suidgeest, E., van der Weerd, L., Mei, H., Baelde, H. J., & Peters, D. J. M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166987 · Cited by 7
Luo, J., Zhang, Y., Jayaprakash, S., Zhuang, L., & He, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115646 · Cited by 7
“In contrast to typical homozygous ADPKD models, the Pkd1 RC/RC model can induce slowly progressed ADPKD and has been extensively utilized in preclinical investigations [123].”
ResultMyocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease
Lichner, Z., Ding, M., Khare, T., Dan, Q., Benítez, R., Praszner, M., Song, X., Saleeb, R., Hinz, B., Pei, Y., et al. (2024) · Cells · doi:10.3390/cells13110984 · Cited by 7
“…blocks of the kidneys of 12-month-old PKD1 RC/RC (n = 3) and control littermates (WT, n = 3), as well as 3-month-old PKD2 WS25/ − (n = 6) and control littermates (PKD2 WS25/+, n = 3) [44,55,56], were processed at the Keenan Research Centre for Biomedical Sciences, St Michael’s Hospital.”
BackgroundMethodInfluentialGombart, S. K., Houghtaling, S. R., Ho, T.-H., & Beier, D. R. (2025) · Journal of Cell Science · doi:10.1242/jcs.264133 · Cited by 7
Xu, T., Chen, M., Xu, Q., Xue, C., Fu, L., Ling, K., Hu, J., & Mei, C. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2707216 · Cited by 7
Prenatal diagnosis of polycystic kidney caused by biallelic hypomorphic variants in the PKD1 gene
Zheng, Y., Wong, L., Kwan, A. H. W., Dong, Z., Kwok, K. Y., Choy, K. W., Dai, H., & Cao, Y. (2023) · Prenatal Diagnosis · doi:10.1002/pd.6419 · Cited by 7
Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models
Chaudhary, A., He, Z., Atwood, D. J., Miyazaki, M., Oto, Ö. A., Davidoff, A. W., & Edelstein, C. L. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00372.2023 · Cited by 7
Gu, J., Liu, F., Li, L., & Mao, J. (2025) · Biomedicines · doi:10.3390/biomedicines13020523 · Cited by 7
“These models are particularly useful for investigating the molecular mechanisms underlying cystogenesis and disease progression [66,67].”
Autosomal Dominant Polycystic Kidney Disease Induced by Ciliary Defects
Park, J. H. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch15 · Cited by 7
“R3277C) shows progressive PKD phenotype with elongated cilia of the renal collecting duct cells (66).”
BackgroundFunctional megalin is expressed in renal cysts in a mouse model of adult polycystic kidney disease
Nielsen, M. L., Mundt, M. C., Lildballe, D. L., Rasmussen, M. B., Sunde, L., Torres, V. E., Harris, P. C., & Birn, H. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab088 · Cited by 7
“In addition, the original article states that reduced renal function was observed in mice from 9 months of age [9], which suggests the observations in this study compare to a time before glomerular filtration rate starts to decline in humans.”
BackgroundResultInfluentialSelf-citationQian, F. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch11 · Cited by 7
“Cystogenesis will begin when the level of functional PC1 is below the critical threshold (10, 11).”
BackgroundGewin, L. S., Summers, M. E., Harral, J. W., Gaskill, C. F., Khodo, S. N., Neelisetty, S., Sullivan, T. M., Hopp, K., Reese, J., Klemm, D. J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00629.2018 · Cited by 7
Self-citationSlowing Polycystic Kidney Disease by Fasting
Boletta, A. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101113 · Cited by 7
Renal tissue-resident macrophages promote cystogenesis in early polycystic kidney disease
Karl, R., Ashraf, A. P. K., Viola, M. F., Hopp, K., Mass, E., & Wachten, D. (2025) · Journal of Cell Science · doi:10.1242/jcs.263992 · Cited by 6
“Here, we use an orthologous mouse model of ADPKD1 (Arroyo et al., 2021; Hopp et al., 2012) in a C57BL/6JRcc background ( Pkd1 RC/RC ) to model a slow disease onset, characterize macrophage abundance and phenotype during disease progression, and investigate their effect on cyst development in a 3D…”
Self-citationc-JUN n-Terminal Kinase (JNK) Signaling in Autosomal Dominant Polycystic Kidney Disease
Smith, A. O., Jonassen, J. A., Preval, K. M., Davis, R. J., & Pazour, G. J. (2022) · Journal of Cellular Signaling · doi:10.33696/signaling.3.068 · Cited by 6
“Interestingly, mice homozygous for the Pkd1RC mutation developed focal cysts even though every cell in the tubule was genetically identical [58].”
BackgroundResultDurkie, M., Watson, C. M., Winship, P. R., Hogg, A.-C., Nyanhete, R., Cooley, S. M., Valluru, M. K., Shaw-Smith, C. J., Bingham, C., Gilchrist, M., et al. (2023) · Human Mutation · doi:10.1155/2023/5597005 · Cited by 6
“Studies using an engineered mouse model showed it to be a temperature-sensitive folding/trafficking mutant with approximately 20% retained activity in a compound heterozygous Arg3277Cys/null mouse mutant, consistent with a hypomorphic effect [11].”
CFTR and PC2, partners in the primary cilia in autosomal dominant polycystic kidney disease
Yanda, M. K., Ciobanu, C., Guggino, W. B., & Cebotaru, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00197.2023 · Cited by 6
Mechanistic complement of autosomal dominant polycystic kidney disease: the role of aquaporins
Lan, Q., Li, J., Zhang, H., Zhou, Z., Fang, Y., & Yang, B. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02446-4 · Cited by 6
“When PC1-PC2 signaling is diminished due to a mutation below a certain threshold [44, 45], the inhibitory effect of CDCA is weakened, and during this long-term process, the tubules begin to remodel the surrounding basement membrane and parenchyma, accompanied by cell proliferation and morphological…”
Matsuura, R., Honda, K., Hamasaki, Y., Doi, K., Noiri, E., & Nangaku, M. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.061 · Cited by 6
Germino, G. G., & Guay‐Woodford, L. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00040-8 · Cited by 6
Zhang, Y., Plansinis, M., Peak, S., Weber, E., Wei, A., Xu, Y., Ross, M., Leagjeld, A., Wallace, D. P., & Zhang, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111749 · Cited by 5
Cheng, A. S., Li, L. X., Zhou, J. X., Harris, P. C., Calvet, J. P., & Li, X. (2025) · Kidney International · doi:10.1016/j.kint.2025.12.004 · Cited by 5
Self-citationLakhia, R., Song, C., Biggers, L. M., Zumwalt, M., Alvarez, J., Somasundarum, A., Ramalingam, H., Cobo-Stark, P., & Patel, V. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkaf1538 · Cited by 5
“We introduced this modification into the hypomorphic Pkd1 RC3277 allele, enabling the simultaneous assessment of the cis-regulatory impact on Pkd1 expression and ADPKD progression [ 14 ].”
Metadata
- Authors
- Hopp, K., Ward, C. J., Hommerding, C. J., Nasr, S. H., Tuan, H.-F., Gainullin, V. G., Rossetti, S., Torres, V. E., & Harris, P. C.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Harris, Peter C.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-15
- Volume
- 122
- Issue
- 11
- Pages
- 4257-4273
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3484456
- OpenAlex
- W2085346322
- Cited by
- 442
- References
- 112
- Citations by year
- 2026: 34 · 2025: 34 · 2024: 45 · 2023: 43 · 2022: 44 · 2021: 44 · 2020: 38 · 2019: 23 · 2018: 19 · 2017: 20 · 2016: 21 · 2015: 31 · 2014: 26 · 2013: 18
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic (DK090728)
- American Heart Association
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-058816, DK090728, R01DK044863, P30DK090728, R01DK058816)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Keywords
- autosomal dominant polycystic kidney disease, polycystin-1, PKD1, hypomorphic allele, dosage dependence, disease severity, cyst formation, knockin mouse model, primary cilia, collecting duct, temperature-sensitive mutants, phenotypic variability
- MeSH terms
- Animals, Disease Models, Animal, Severity of Illness Index, Polycystic Kidney, Autosomal Dominant, Protein Folding, Amino Acid Substitution, Mutation, Missense, Animals, Genetically Modified, TRPP Cation Channels, Mice, Gene Knock-In Techniques, Genetic Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.